MediciNova, Inc.
http://www.medicinova.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MediciNova, Inc.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
End Game: Adrenomed Targets Global Reach For Sepsis Candidate
German biotech Adrenomed has proof-of-concept data showing its sepsis drug can cut mortality by 67%. Now, it needs money to move the candidate into Phase IIb/III trials.
US FDA’s Missed User Fee Goals Spiked In 2023 – And Not Just Because Of COVID-19
CDER missed six goal dates among its 2023 novel approvals, reflecting safety concerns as well as pandemic-related inspection delays; Duchenne muscular dystrophy accelerated approval disagreements caused the biologics center’s lone missed goal.
Finance Watch: Syndax Has A Standout Post-ASH Offering As Peers Scramble For Cash
Public Company Edition: Syndax grossed $230m in a follow-on public offering based on positive results for its menin inhibitor in leukemia, but the FOPO was an outlier relative to other companies, which relied on private placements, debt and other options to raise cash in a tough market.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Avigen, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice